Bionano Genomics, Inc. Balance Sheet
BNGO|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$74M
FY2025
Cash
$3M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$44M
FY2025
Bionano Genomics, Inc. had $74M in total assets and $44M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -59.4% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M | $38.4M | $17.3M | $16.5M |
| Accounts Receivable | $5.2M | $4.8M | $9.3M | $7.0M | $4.9M | $2.8M | $6.3M | $4.5M |
| Inventory | $7.8M | $13.3M | $27.6M | $29.8M | $12.4M | $3.3M | $3.4M | $1.1M |
| Current Assets | $45.4M | $39.5M | $140.1M | $157.3M | $272.4M | $46.8M | $28.3M | $23.0M |
| PP&E (Net) | $14.8M | $19.2M | $23.3M | $18.0M | $10.3M | $4.9M | $1.9M | $1.8M |
| Goodwill | - | - | $0 | $77.3M | $56.2M | $7.2M | $0 | - |
| Total Assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M | $60.5M | $30.2M | $24.8M |
| Current Liabilities | $22.9M | $37.3M | $100.0M | $35.9M | $21.8M | $8.9M | $26.4M | $4.5M |
| Total Debt | - | - | - | - | $0 | $16.3M | $20.1M | $9.0M |
| Shareholders' Equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M | $35.1M | $3.6M | $10.1M |